Scinai Immunotherapeutics ⚠ Under review

Under review — some data on this profile may be inaccurate and is being re-verified.

A biopharmaceutical company developing immunology therapies and providing CDMO services.

Health Tech & Life Sciences
Acquired by Pincell srl
Public Jerusalem, Israel Founded 2003
Last updated 2026-07-20
Total raised
$37.6M
Last: Undisclosed Round 2025-10
Stage
Public
Founded
2003
Headcount
45
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences

About

Scinai Immunotherapeutics Ltd. is an Israeli biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products. The company specializes in in-house development of inflammation and immunology biological therapeutic products, including a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs. Additionally, Scinai operates a boutique Contract Development and Manufacturing Organization (CDMO) providing services for drug development and GMP and non-GMP manufacturing for pre-clinical and clinical studies. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name in September 2023. Scinai's R&D unit focuses on inflammation and immunology (I&I) biological therapeutics, including anti-IL-17 NanoAb candidates for psoriasis and additional NanoAbs from collaborations with the Max Planck Society and University Medical Center Göttingen. The company also offers CDMO services, including biological drug development, analytical method development, process development, and clinical cGMP manufacturing services, with a focus on early-stage biotech clients in Israel, the United States, and Europe.

Funding history · 13 rounds · $37.6M total

2025-10
Grant $218K
★ Israel Innovation Authority
2025-03
Undisclosed Round $10.0M
★ Yorkville Advisors Global, LP
2023-08
PIPE $1.3M
2022-11
Follow-on PO Undisclosed
2021-11
Follow-on PO Undisclosed
2019-06
PIPE $16.7M
2019-03
Grant $4.5M
2017-08
Follow-on PO Undisclosed
2017-07
Grant $750K
2016-12
PIPE $2.9M
2015-04
Follow-on PO Undisclosed
2014-08
Grant $1.3M
2007-12
Follow-on PO Undisclosed

Headcount over time

From 18 (2017-01) to 28 (2026-03) · +10 (+56%) · 18 points · source: Finder history + radar grounding
380 2017-01 2026-03

Q&A

What is the current status of Scinai Immunotherapeutics?
Scinai Immunotherapeutics was acquired by Pincell srl in June 2025.
What was Scinai Immunotherapeutics' former name?
Scinai Immunotherapeutics was formerly known as BiondVax Pharmaceuticals.
Where is Scinai Immunotherapeutics headquartered?
Scinai Immunotherapeutics is headquartered in Jerusalem, Israel, specifically at the Jerusalem BioPark, Hadassah Ein Kerem Campus.
How many employees does Scinai Immunotherapeutics have?
Scinai Immunotherapeutics has 11-50 employees.
What is Scinai Immunotherapeutics' primary focus?
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products, primarily for the treatment of autoimmune and infectious diseases.
When was Scinai Immunotherapeutics founded?
Scinai Immunotherapeutics was founded in July 2003.
What was the most recent funding event for Scinai Immunotherapeutics?
In October 2025, Scinai Immunotherapeutics received a grant of $246,000 from the Israel Innovation Authority.
Who are the key executives at Scinai Immunotherapeutics?
The key executives at Scinai Immunotherapeutics include Amir Reichman (CEO), Elad Mark (COO), and Tamar Ben-Yedidia, PhD (CSO).
What is Scinai Immunotherapeutics' total raised capital?
Scinai Immunotherapeutics has raised a total of $63,937,200 USD.

Team · 5

Ronald Babecoff
Founder · Founder
Rami Epstein
Founder · Founder

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesHealthcareProvidersPatientsLife SciencesPharmaceuticals
Business model
B2B2CB2B

Highlights

1 PatentsVerified

Tags

immunotherapyautoimmune-diseasespharmaceuticalsviral-diseasesbiotechnologytherapeuticsinfectious-diseasedrug-discoverytreatmentsdrug-deliverybiopharmaceuticalvaccinespatientsnanotechnology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitescinai.com/
LinkedInlinkedin.com/company/725313
Facebookfacebook.com/ScinaiSCNI
YouTubeyoutube.com/@Scinai
Instagraminstagram.com/scinai.immunotherapeutics

Identifiers & details

Legal nameScinai Immunotherapeutics Ltd.
Former namesBiondVax Pharmaceuticals
Founded2003-7
Employees (exact)45
Market cap$2.3M
Status reasonAcquired by Pincell srl on Jun, 2025

Acquisitions & public offerings

Acquired by Pincell srl 2025-06

TypeDateExchangeTickerAmount
2022-12$8.0M
2021-12$9.8M
2017-09$9.0M
2015-05$9.5M
2008-01

Radar intelligence

Web history (Wayback)

Domainscinai.com

Certificate / subdomain footprint

Subdomains4

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)513436105
Statusפעילה
Corp typeישראלית חברה ציבורית
Incorporated2003-07-22
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2023
Active charges / liens0
Registry events2 — people (1), other (1)
Registered addressקרית הדסה בנין JBP 1 ירושלים

Recent registry events

DateEvent
2026-06-23עדכון דירקטורים-הסרת דירקטור
2026-07-06שינוי סיווג חברה